Cellular and molecular mechanisms of metformin: an overview
Open accessThe DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Abstract
Considerable efforts have been made since the 1950s to better understand the cellular and molecular mechanisms of action of metformin, a potent antihyperglycaemic agent now recommended as the first-line oral therapy for T2D (Type 2 diabetes). The main effect of this drug from the biguanide family is to acutely decrease hepatic glucose production, mostly through a mild and transient inhibition of the mitochondrial respiratory chain complex I. In addition, the resulting decrease in hepatic energy status activates AMPK (AMP-activated protein kinase), a cellular metabolic sensor, providing a generally accepted mechanism for the action of metformin on hepatic gluconeogenesis. The demonstration that respiratory chain complex I, but not AMPK, is the primary target of metformin was recently strengthened by showing that the metabolic effect of the drug is preserved in liver-specific AMPK-deficient mice. Beyond its effect on glucose metabolism, metformin has been reported to restore ovarian function in PCOS (polycystic ovary syndrome), reduce fatty liver, and to lower microvascular and macrovascular complications associated with T2D. Its use has also recently been suggested as an adjuvant treatment for cancer or gestational diabetes and for the prevention in pre-diabetic populations. These emerging new therapeutic areas for metformin will be reviewed together with recent findings from pharmacogenetic studies linking genetic variations to drug response, a promising new step towards personalized medicine in the treatment of T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In PCOS, metformin reduces insulin resistance and inhibits ovarian androgen production via effects on steroidogenic acute regulatory protein and 17alphahydroxylase (Diamanti-Kandarakis et al. , 2010; Viollet et al. , 2012).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Viollet et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“a drug that is currently being used to treat type II diabetic patients, metformin [74], can activate AMPK”
From Senescence of T Lymphocytes: Implications for Enhancing Human Immunity (2016) · cites this paper as [74]
The cited source says what the claim attributes to it.
In the citing paper
“Given the evidence that metformin acts through the mitochondrial electron transport chain (ETC) by inhibiting complex I(46, 210–212) (Figure 8)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [46]
In the citing paper
“By far the most important mechanism is the reduction in hepatic glucose production that is considered mediated by the activation of the global energy sensor in cells, adenosine monophosphate-activated protein kinase (AMPK) (Figure 1).(46)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 4×
“Thus, AMPK activation by metformin induces the phosphorylation and inactivation of acetyl CoA carboxylase (ACC), an important rate-controlling enzyme for the synthesis of malonylCoA, which is both a critical precursor for the biosynthesis of fatty acids and a potent inhibitor of mitochondrial fatty acid oxidation [17].”
BackgroundInfluentialHyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Furthermore, the authors found a doseresponse relationship between duration of exposure to metformin and cancer incidence [106].”
BackgroundGiovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 25×
“Metformin most likely does not directly activate either LKB1 or AMPK as the drug does not influence the phosphorylation of AMPK by LKB1 in cell-free assay [21].”
BackgroundInfluential
Cited by
Items 201–300 of 1,001
Cellular Senescence in Intervertebral Disc Aging and Degeneration
Patil, P. R., Niedernhofer, L. J., Robbins, P. D., Lee, J., Sowa, G., & Vo, N. N. (2018) · Current Molecular Biology Reports · doi:10.1007/s40610-018-0108-8 · Cited by 100
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Zhang, M., Feng, R., Yang, M., Cheng, Q., Wang, Z., Liu, W., & Ma, J. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000717 · Cited by 93
Trotta, A. P., Gelles, J. D., Serasinghe, M. N., Loi, P., Arbiser, J. L., & Chipuk, J. E. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.786442 · Cited by 96
Metformin intake associates with better cognitive function in patients with Huntington's disease
Hervás, D., Fornés, V., Gómez-Escribano, A. P., Sequedo, M. D., Peiró, C., Millán, J. M., & Vázquez‐Manrique, R. P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179283 · Cited by 91
Host quality induces phenotypic plasticity in a wing polyphenic insect
Lin, X., Xu, Y., Jiang, J., Lavine, M., & Lavine, L. C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721473115 · Cited by 89
Stem-cell based organ-on-a-chip models for diabetes research
Rogal, J., Zbinden, A., Schenke‐Layland, K., & Loskill, P. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.010 · Cited by 93
Ma, L., Wei, J., Wan, J., Wang, W., Wang, L., Yuan, Y., Yang, Z., Liu, X., & Ming, L. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1090-6 · Cited by 89
Filippov, S., Pinkosky, S. L., Lister, R. J., Pawloski, C., Hanselman, J. C., Cramer, C. T., Srivastava, R. A. K., Hurley, T. R., Bradshaw, C. D., Spahr, M. A., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m035212 · Cited by 90
Hall, D. T., Griss, T., Ma, J. F., Sanchez, B. J., Sadek, J., Tremblay, A. M. K., Mubaid, S., Omer, A., Ford, R. J., Bedard, N., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708307 · Cited by 88
“In contrast, the biguanide metformin inhibits Complex I of the electron transport chain, leading to an indirect activation of AMPK by increasing cytoplasmic AMP levels (Viollet et al, 2012).”
BackgroundBiguanides: Species with versatile therapeutic applications
Kathuria, D., Raul, A. D., Wanjari, P. J., & Bharatam, P. V. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113378 · Cited by 96
Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning
Gadducci, A., Biglia, N., Tana, R., Cosio, S., & Gallo, M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.06.006 · Cited by 91
Guimarães, T. A., Farias, L. C., Santos, E. S., Fraga, C. A. D. C., Orsine, L. A., Teles, L. D. F., Feltenberger, J. D., de Jesus, S. F., de Souza, M. G., Santos, S. H. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10842 · Cited by 94
Adak, T., Samadi, A., Ünal, A. Z., & Sabuncuoğlu, S. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.12.023 · Cited by 91
Kulkarni, S. S., Joffraud, M., Boutant, M., Ratajczak, J., Gao, A. W., Maclachlan, C., Hernandez-Alvarez, M. I., Raymond, F., Metairon, S., Descombes, P., et al. (2016) · Diabetes · doi:10.2337/db15-1725 · Cited by 86
Reprogramming of central carbon metabolism in cancer stem cells
Wong, T. L., Che, N., & Ma, S. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.05.012 · Cited by 97
Valtorta, S., Dico, A. L., Raccagni, I., Gaglio, D., Belloli, S., Politi, L. S., Martelli, C., Diceglie, C., Bonanomi, M., Ercoli, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23028 · Cited by 92
Tseng, C. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa136 · Cited by 89
Adenosine monophosphate–activated protein kinase in diabetic nephropathy
Kim, Y., & Park, C. W. (2016) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2016.02.004 · Cited by 91
Park, M.-J., Lee, S.-Y., Moon, S., Son, H., Lee, S., Kim, E., Byun, J. K., Shin, D. Y., Park, S., Yang, C. W., et al. (2016) · Translational research · doi:10.1016/j.trsl.2016.03.006 · Cited by 89
Banerjee, J., Bruckbauer, A., & Zemel, M. B. (2016) · Metabolism · doi:10.1016/j.metabol.2016.06.011 · Cited by 86
Metabolic Profiles Associated With Metformin Efficacy in Cancer
Andrzejewski, S., Siegel, P. M., & St‐Pierre, J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00372 · Cited by 90
Metformin upregulates mitophagy in patients with T2DM: A randomized placebo‐controlled study
Bhansali, S., Bhansali, A. K., Dutta, P. R., Walia, R., & Dhawan, V. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14834 · Cited by 84
Shpakov, A. O. (2021) · Pharmaceuticals · doi:10.3390/ph14010042 · Cited by 91
Gamad, N., Malik, S., Suchal, K., Vasisht, S., Tomar, A., Arava, S. K., Arya, D. S., & Bhatia, J. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.101 · Cited by 89
Lee, J. W., Shin, Y.-J., Kim, H., Kim, H., Kim, J., Min, S.-A., Kim, P., Yu, S. D., & Park, K. (2018) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2018.12.084 · Cited by 87
Crosstalk between gut microbiota and antidiabetic drug action
Kyriachenko, Y., Falalyeyeva, T. M., Korotkyi, O., Molochek, N., & Kobyliak, N. M. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i3.154 · Cited by 85
McNeilly, A. D., Williamson, R., Balfour, D. J. K., Stewart, C. A., & Sutherland, C. D. (2012) · Diabetologia · doi:10.1007/s00125-012-2686-y · Cited by 91
Kasuga, M., Ueki, K., Tajima, N., Noda, M., Ohashi, K., Noto, H., Goto, A., Ogawa, W., Sakai, R., Tsugane, S., et al. (2013) · Cancer Science · doi:10.1111/cas.12203 · Cited by 88
Ljubicic, V., Burt, M., & Jasmin, B. J. (2013) · The FASEB Journal · doi:10.1096/fj.13-238071 · Cited by 90
Metabolism pathways in chronic lymphocytic leukemia
Rozovski, U., Hazan‐Halevy, I., Barzilai, M., Keating, M. J., & Estrov, Z. E. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1106533 · Cited by 92
Abdel-Rahman, R. M., Abdel-Mohsen, A. M., Hrdina, R., Burgert, L., Fohlerová, Z., Pavliňák, D., Sayed, O. N., & Jancar, J. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.04.087 · Cited by 84
Metabolic syndrome and benign prostatic hyperplasia: An update
Ngai, H., Yuen, K. K. S., Ng, C.-M., Cheng, C., & Chu, S.-K. P. (2017) · Asian journal of urology · doi:10.1016/j.ajur.2017.05.001 · Cited by 90
Sarkaki, A., Farbood, Y., Badavi, M., Khalaj, L., Khodagholi, F., & Ashabi, G. (2015) · Metabolic Brain Disease · doi:10.1007/s11011-015-9677-x · Cited by 84
Luo, X., Li, R., & Yan, L. (2015) · Journal of Diabetes Research · doi:10.1155/2015/512618 · Cited by 90
Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice
Zhang, Q., Tang, W., Deater, M., Phan, N., Marcogliese, A. N., Li, H., Al-Dhalimy, M., Major, A. M., Olson, S. B., Monnat, R. J., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683490 · Cited by 81
Supruniuk, E., Mikłosz, A., & Chabowski, A. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00923 · Cited by 86
Metformin: The hidden chronicles of a magic drug
Mahmood, K., Naeem, M., & Rahimnajjad, N. A. (2012) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.10.011 · Cited by 87
Krishan, S., Richardson, D. R., & Sahni, S. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.095810 · Cited by 88
Yan, H., Zhou, H.-F., Hu, Y., & Pham, C. T. N. (2015) · Journal of Rheumatic Diseases and Treatment · doi:10.23937/2469-5726/1510005 · Cited by 86
Metformin-stimulated AMPK-α1 promotes microvascular repair in acute lung injury
Jian, M., ALEXEYEV, M. F., Wolkowicz, P. E., Zmijewski, J. W., & Creighton, J. R. (2013) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00173.2013 · Cited by 80
Jiang, X., Ruan, X., Xue, Y., Yang, S., Shi, M., & Wang, L.-N. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8708236 · Cited by 86
mTOR co-targeting strategies for head and neck cancer therapy
Wang, Z., Valera, J. L. C., Zhao, X., Chen, Q., & Gutkind, J. S. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9688-7 · Cited by 86
Modulation of autophagy for neuroprotection and functional recovery in traumatic spinal cord injury
Ray, S. K. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.276322 · Cited by 82
Metformin and Vitamin B12 Deficiency: Where Do We Stand?
Ahmed, M. A. (2016) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3pk7p · Cited by 90
Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions
Gutkind, J. S., Molinolo, A., Wu, X., Wang, Z., Nachmanson, D., Harismendy, O., Alexandrov, L. B., Wuertz, B. R. K., Ondrey, F. G., Laronde, D. M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.147096 · Cited by 81
Examining the clinical relevance of metformin as an antioxidant intervention
Buczyńska, A., Sidorkiewicz, I., Kretowski, A. J., & Adamska, A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1330797 · Cited by 84
Nakamichi, N., Shima, H., Asano, S., Ishimoto, T., Sugiura, T., Matsubara, K., Kusuhara, H., Sugiyama, Y., Sai, Y., Miyamoto, K., et al. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23595 · Cited by 84
Metformin and Berberine Prevent Olanzapine-Induced Weight Gain in Rats
Hu, Y., Young, A. J., Ehli, E. A., Nowotny, D., Davies, P. S., Droke, E. A., Soundy, T. J., & Davies, G. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093310 · Cited by 76
Pro-angiogenic Role of Insulin: From Physiology to Pathology
Escudero, C., Herlitz, K., Troncoso, F., Guevara, K., Acurio, J., Aguayo, C. R., Godoy, A., & González, M. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00204 · Cited by 84
Molecular mechanisms underlying metabolic syndrome: the expanding role of the adipocyte
Armani, A., Berry, A., Cirulli, F., & Caprio, M. (2017) · The FASEB Journal · doi:10.1096/fj.201601125rrr · Cited by 73
Reed, S., Taka, E., Darling‐Reed, S., & Soliman, K. F. A. (2025) · Cells · doi:10.3390/cells14141064 · Cited by 82
He, Z., Zhou, Z., Yang, Y., Yang, T., Pan, S., Qiu, J., & Zhou, S. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12332 · Cited by 83
Grimm, M., Cetindis, M., Lehmann, M., Biegner, T., Munz, A., Teriete, P., Kraut, W., & Reinert, S. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-208 · Cited by 62
AMPK promotes osteogenesis and inhibits adipogenesis through AMPK-Gfi1-OPN axis
Wang, Y., Qu, X., Yang, Y., Han, X., Wang, L., Qiao, H., Fan, Q., Tang, T., & Dai, K. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.06.004 · Cited by 76
Metformin as a Therapeutic Target in Endometrial Cancers
Lee, T. Y., Martinez‐Outschoorn, U., Schilder, R. J., Kim, C. H., Richard, S. D., Rosenblum, N. G., & Johnson, J. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00341 · Cited by 77
Metformin: prevention of genomic instability and cancer: a review
Najafi, M., Cheki, M., Rezapoor, S., Geraily, G., Motevaseli, E., Carnovale, C., Clementi, E., & Shirazi, A. (2018) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2018.01.007 · Cited by 75
Zhou, P.-T., Li, B., Liu, F.-R., Zhang, M.-C., Wang, Q., Li, Y.-Y., Xu, C., Liu, Y.-H., Yao, Y., & Li, D. (2017) · Oncotarget · doi:10.18632/oncotarget.15692 · Cited by 70
Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities
Pulito, C., Mori, F., Sacconi, A., Goeman, F., Ferraiuolo, M. A., Pasanisi, P., Campagnoli, C., Berrino, F., Fanciulli, M., Ford, R. J., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2017.22 · Cited by 77
Placental mitochondrial dysfunction with metabolic diseases: Therapeutic approaches
Hebert, J. F., & Myatt, L. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165967 · Cited by 81
Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity
Zemel, M., & Bruckbauer (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s40840 · Cited by 71
Chai, X.-Q., Chu, H., Yang, X., Meng, Y.-P., Shi, P., & Gou, S. (2015) · Scientific Reports · doi:10.1038/srep14404 · Cited by 75
Li, Y., Wang, M., Zhi, P., You, J., & Gao, J. (2017) · Oncotarget · doi:10.18632/oncotarget.23187 · Cited by 79
Sharma, P., Hajam, Y. A., Kumar, R., & Rai, S. (2021) · Phytomedicine Plus · doi:10.1016/j.phyplu.2021.100188 · Cited by 78
A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer
Khan, A. S., & Frigo, D. E. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2016.272 · Cited by 72
Haikala, H. M., Anttila, J. M., Marques, E., Raatikainen, T., Ilander, M., Hakanen, H., Ala-Hongisto, H., Savelius, M., Balboa, D., Von Eyss, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08541-2 · Cited by 75
The role of the TOR pathway in mediating the link between nutrition and longevity
Lushchak, O., Strilbytska, O., Piskovatska, V., Storey, K. B., Koliada, A., & Vaiserman, A. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.03.005 · Cited by 73
Alolga, R. N., Nuer-Allornuvor, G. F., Kuugbee, E. D., Yin, X., & Ma, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104630 · Cited by 76
Demir, Ü., Koehler, A., Schneider, R., Schweiger, S., & Klocker, H. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-52 · Cited by 79
Metformin in dermatology: an overview
Badr, D. T., Kurban, M., & Abbas, O. M. (2013) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12116 · Cited by 77
Cheng, K., & Hao, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122000 · Cited by 77
Konagaya, Y., Terai, K., Hirao, Y., Takakura, K., Imajo, M., Kamioka, Y., Sasaoka, N., Kakizuka, A., Sumiyama, K., Asano, T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.113 · Cited by 78
Cheki, M., Shirazi, A., Mahmoudzadeh, A., Bazzaz, J. T., & Hosseinimehr, S. J. (2016) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2016.09.001 · Cited by 72
“Metformin (dimethylbiguanide) is an oral hypoglycemic agent that is widely used in the management of non-insulin-dependent diabetes mellitus [6].”
BackgroundMetformin prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction
Cavaglieri, R. C., Day, R. T., Féliers, D., & Abboud, H. E. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.006 · Cited by 76
Crosstalk between autophagy and insulin resistance: evidence from different tissues
Sadeghi, A., Niknam, M., Momeni‐Moghaddam, M. A., Shabani, M., Aria, H., Bastin, A., Teimouri, M., Meshkani, R., & Akbari, H. (2023) · European journal of medical research · doi:10.1186/s40001-023-01424-9 · Cited by 77
Kim, Y., Kim, S., Cho, S., Park, J., Choi, I. J., Lee, Y. J., Lee, E. K., Kook, M., Kim, C. G., Ryu, K. W., et al. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12660 · Cited by 76
An Update on the Pharmacogenomics of Metformin: Progress, Problems and Potential
Todd, J. N., & Florez, J. C. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.21 · Cited by 77
Are epigenetic drugs for diabetes and obesity at our door step?
Arguelles, A. O., Meruvu, S., Bowman, J. D., & Choudhury, M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.12.001 · Cited by 75
Shivavedi, N., Kumar, M., Tej, G. N. V. C., & Nayak, P. K. (2017) · Brain Research · doi:10.1016/j.brainres.2017.08.019 · Cited by 78
Low-dose metformin exposure causes changes in expression of endocrine disruption-associated genes
Niemuth, N. J., & Klaper, R. D. (2017) · Aquatic Toxicology · doi:10.1016/j.aquatox.2017.12.003 · Cited by 76
The application of metabolomics in investigating anti-diabetic activity of medicinal plants
Hasanpour, M., Iranshahy, M., & Iranshahi, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110263 · Cited by 76
Zhang, Z., Yang, J.-S., Hao, D., Liu, T.-J., & Jing, Q. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s312623 · Cited by 77
Wu, J., Puppala, D., Feng, X., Monetti, M., Lapworth, A. L., & Geoghegan, K. F. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.508747 · Cited by 64
Activation of the ATF2/CREB-PGC-1α pathway by metformin leads to dopaminergic neuroprotection
Kang, H., Khang, R., Ham, S., Jeong, G. R., Kim, H., Jo, M., Lee, B. D., Lee, Y. I., Jo, A., Park, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18122 · Cited by 77
Effects of environmentally relevant metformin exposure on Japanese medaka (Oryzias latipes)
Ussery, E. J., Bridges, K. N., Pandelides, Z., Kirkwood, A. E., Bonetta, D. T., Venables, B. J., Guchardi, J., & Holdway, D. A. (2018) · Aquatic Toxicology · doi:10.1016/j.aquatox.2018.10.003 · Cited by 71
Protonation–deprotonation and structural dynamics of antidiabetic drug metformin
Hernández, B., Pflüger, F., Kruglik, S. G., Cohen, R., & Ghomi, M. (2015) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2015.04.041 · Cited by 71
Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes
Kato, H., Nagai, Y., Ohta, A., Tenjin, A., Nakamura, Y., Tsukiyama, H., Sasaki, Y., Fukuda, H., Ohshige, T., Terashima, Y., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.008 · Cited by 70
Revisiting the mechanisms of metformin action in the liver
Viollet, B., & Foretz, M. (2013) · Annales d Endocrinologie · doi:10.1016/j.ando.2013.03.006 · Cited by 82
Self-citationter Horst, K. W., Gilijamse, P. W., de Weijer, B. A., Kiliçarslan, M., Ackermans, M. T., Nederveen, A. J., Nieuwdorp, M., Romijn, J. A., & Serlie, M. J. M. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00182 · Cited by 79
A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
Hossain, N., Kanwar, P., & Mohanty, S. R. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/7109270 · Cited by 75
“What's in a structure?” The story of biguanides
Kathuria, D., Bankar, A. A., & Bharatam, P. V. (2017) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2017.08.100 · Cited by 77
Satarug, S. (2019) · Toxics · doi:10.3390/toxics7020025 · Cited by 74
Hypoxia, AMPK activation and uterine artery vasoreactivity
Skeffington, K. L., Higgins, J. S., Mahmoud, A. D., Evans, A. M., Sferruzzi‐Perri, A. N., Fowden, A. L., Yung, H. W., Burton, G. J., Giussani, D. A., & Moore, L. G. (2016) · The Journal of Physiology · doi:10.1113/jp270995 · Cited by 69
Adedeji, H. A., Ishola, I. O., & Adeyemi, O. O. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.10.014 · Cited by 71
Tyszka-Czochara, M., Konieczny, P., & Majka, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020462 · Cited by 65
The Gut Microbiome, Metformin, and Aging
Induri, S. N. R., Kansara, P., Thomas, S. C., Xu, F., Saxena, D. B., & Li, X. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051920-093829 · Cited by 70
In Vitro and In Vivo Antidiabetic Potential of Monoterpenoids: An Update
Kury, L. T. A., Abdoh, A., Ikbariah, K., Sadek, B. S., & Mahgoub, M. (2021) · Molecules · doi:10.3390/molecules27010182 · Cited by 78
Hu, M., Ye, P., Liao, H., Chen, M., & Yang, F. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2961954 · Cited by 72
Kim, K., Abelman, S. H., Yano, N., Ribeiro, J. R., Singh, R. K., Tipping, M., & Moore, R. G. (2015) · Scientific Reports · doi:10.1038/srep14296 · Cited by 80
Parkinson';s Disease, Diabetes and Cognitive Impairment
Ashraghi, M. R., Pagano, G., Polychronis, S., Niccolini, F., & Politis, M. (2016) · Recent Patents on Endocrine Metabolic & Immune Drug Discovery · doi:10.2174/1872214810999160628105549 · Cited by 70
Metadata
- Authors
- Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F.
- Affiliations
- INSERM, U1016, Institut Cochin, Paris, France
- Leiden University Medical Center (NL)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Leclerc, Jocelyne
- Foretz, Marc
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2011-11-11
- Volume
- 122
- Issue
- 6
- Pages
- 253-270
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- PMC
- PMC3398862
- OpenAlex
- W2154024784
- Cited by
- 1,720
- References
- 167
- Citations by year
- 2026: 63 · 2025: 85 · 2024: 96 · 2023: 103 · 2022: 106 · 2021: 143 · 2020: 155 · 2019: 135 · 2018: 141 · 2017: 156 · 2016: 137 · 2015: 144 · 2014: 117 · 2013: 104 · 2012: 34
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- metformin, type 2 diabetes, biguanides, AMPK, mitochondrial complex I inhibition, hepatic gluconeogenesis, hepatic glucose production, polycystic ovary syndrome, hepatic steatosis, diabetes complications, adjuvant cancer therapy, gestational diabetes mellitus, prediabetes, pharmacogenetics, personalized medicine
- MeSH terms
- Animals, Cardiovascular System, Diabetic Nephropathies, Female, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Polycystic Ovary Syndrome, Circadian Clocks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.